Special Issue

Atrial Fibrillation: New Insights and Perspectives

Message from the Guest Editors

Atrial fibrillation (AF) represents the most common sustained arrhythmia, associated with substantial mortality and morbidity, particularly in patients with heart failure (HF). The current standard of care, transcatheter pulmonary vein isolation (PVI) using thermal ablation techniques, has been proven to show symptom relief but also benefits in patients with HF or persistent AF. Despite these benefits, thermal ablation carries a risk of collateral tissue damage. In recent years, new insights in the causes of AFib evolution as well as in treatment efficacy have been found. For example, pulsed field ablation (PFA), a nonthermal technique based on irreversible electroporation, has emerged as a promising alternative to the conventional thermal ablation method. Accordingly, new advances in AF knowledge and treatment should be focused on in terms of the latest scientific data and releases.

Guest Editors

Dr. Jean-Baptiste Guichard

Institut Clínic Cardiovascular (ICCV), Hospital Clínic, Universitat de Barcelona, Catalonia, Spain

Prof. Dr. Antoine Da Costa

Cardiology Department, Centre Hospitalier Universitaire de Saint Etienne, Saint-Etienne, France

Deadline for manuscript submissions

30 June 2026



Journal of
Cardiovascular
Development and
Disease

an Open Access Journal by MDPI

Impact Factor 2.3 CiteScore 3.7 Indexed in PubMed



mdpi.com/si/240846

Journal of Cardiovascular Development and Disease Editorial Office MDPI, Grosspeteranlage 5 4052 Basel, Switzerland Tel: +41 61 683 77 34 icdd@mdbi.com

mdpi.com/journal/jcdd





Journal of Cardiovascular Development and Disease

an Open Access Journal by MDPI

Impact Factor 2.3 CiteScore 3.7 Indexed in PubMed





Message from the Editor-in-Chief

The primary goal of the *Journal of Cardiovascular Development and Disease* (*JCDD*, ISSN 2308-3425) is to provide cardiovascular scientists a platform to publish their work in a quick and efficient way. Topics can range from studies designed to decipher the events underlying early heart development to studies focusing on the origins of congenital and acquired heart disease. Papers submitted to *JCDD* undergo a fast, yet thorough, peer-review process. In this process, we will apply strict ethical policies and standards. *JCDD* guarantees fast dissemination of results to a large scientific audience

Editor-in-Chief

Prof. Dr. Thomas Brand

National Heart & Lung Institute, Imperial College London, South Kensington Campus, London SW7 2AZ, UK

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Cardiac and Cardiovascular Systems) / CiteScore - Q2 (General Pharmacology, Toxicology and Pharmaceutics)

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 28.8 days after submission; acceptance to publication is undertaken in 2.9 days (median values for papers published in this journal in the first half of 2025).

